Price T Rowe Associates Inc. MD Has $56.60 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Price T Rowe Associates Inc. MD reduced its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,402,452 shares of the company's stock after selling 233,841 shares during the period. Price T Rowe Associates Inc. MD owned about 2.36% of Dyne Therapeutics worth $56,603,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its stake in Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after acquiring an additional 698 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares during the period. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after purchasing an additional 1,249 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Dyne Therapeutics by 11.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock valued at $508,000 after purchasing an additional 2,265 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 in the last three months. Company insiders own 20.77% of the company's stock.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded down $0.13 during midday trading on Friday, reaching $11.86. The stock had a trading volume of 1,040,609 shares, compared to its average volume of 1,560,755. The stock has a market capitalization of $1.35 billion, a P/E ratio of -3.33 and a beta of 1.21. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45. The firm's fifty day simple moving average is $10.58 and its 200-day simple moving average is $18.76.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. HC Wainwright reissued a "buy" rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Scotiabank assumed coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $47.46.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.